◆ 會議時間：2026年3月11-14日
◆ 會議地點：西班牙 巴塞羅那
◆ 會議簡介：
2026年第19屆糖尿病先進技術與治療國際會議（ATTD2026）將于2026年3月11-14日在西班牙巴塞羅那舉行。國際糖尿病先進技術與治療大會（ATTD）是一個獨特的會議，為臨床醫(yī)生和科學家提供了一個世界級的平臺，以介紹、討論和交流快速發(fā)展的糖尿病技術和治療領域的最新見解宣。ATTD將匯集該領域眾多的國際一流專家，共同討論糖尿病治療方面的突破性技術創(chuàng)新成果，并展示新的胰島素類似物、輸送系統(tǒng)、泵、葡萄糖傳感器、閉環(huán)系統(tǒng)等的最新進展。ATTD是與會者了解糖尿病最新研究進展的重要機會，預計有來自世界各地的2500余名代表參會。未經(jīng)本站許可禁止復制摘錄鏡像轉(zhuǎn)載本站任何內(nèi)容-領域國際醫(yī)學會議網(wǎng)（lingyuint.com）。
The 19th International Conference on Advanced Technologies & Treatments for Diabetes - ATTD 2026
Date:
March 11-14, 2026
Venue:
Barcelona, Spain
Pioneering the Future of Diabetes
The landscape of diabetes care is evolving fast and?ATTD 2026?is where technology, innovation, and research converge to shape the next era of treatment.
From AI-driven solutions to the latest in digital health, smart devices, and groundbreaking therapies, this is the conference that defines what’s next in diabetes management.
Join us from March 11-14, 2026, in Barcelona, Spain, for the 19th?International Conference on Advanced Technologies & Treatments for Diabetes.
Connect with global experts, industry leaders, and visionaries pushing the boundaries of what’s possible. Together, let’s harness technology to transform care and improve lives.
The future starts here.
摘要征集：
| Abstract Submission Opened |
Monday, 26 May 2025 |
| Abstract Submission Deadline |
Wednesday, 10 September 2025 midnight CEST (23:59) |
| Regular Abstract Submission Notifications* |
End of November 2025 |
點此提交摘要>>>Submit Abstract>>>
Please read the submission rules before submitting an abstract.
- Abstracts must be submitted online via the website only.
ABSTRACTS SUBMITTED BY EMAIL WILL NOT BE ACCEPTED.
- Presentation Type:?Abstracts may be submitted for oral or e-Poster. (Late breaking abstracts can only be submitted for e-Poster.)
- The Scientific Committee will determine whether the abstract will be accepted for presentation (oral/short oral/e-Poster or Read By Title) or declined.
- Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
- The submission system automatically defines the abstract submitter as a co-author. This cannot be changed after the submission.
Note if you are not a co-author and are submitting on someone else’s behalf, please use their username and login details to submit the abstract. ?
- Publication embargo?– All abstracts are under embargo and will be published at?the start of the ATTD 2026 conference.
Limitations
- The same person may?submit?up to 5 abstracts?regardless of presenting author.
- The same person may serve as a?presenting author?on up to 3 abstracts.
- Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by the?deadline indicated in the notification email,?will be scheduled for presentation and included for publication.
- Submission of an abstract acknowledges your acceptance for the abstract to be published in the official Conference publications.
- The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
- Previously Presented/Published Policy: Abstracts that have been previously presented at another meeting may be submitted. It is preferable that these abstracts contain updates or modifications.
- All accepted abstracts will be published in the peer-reviewed journal Diabetes Technology & Therapeutics, published by Mary Ann Liebert, Inc., Publishers. The Journal is indexed in PubMed.
- The Abstract Submitter grants the Organizers a royalty-free, perpetual, irrevocable nonexclusive license to use, reproduce, publish, translate, distribute, and display the content.
- Abstracts must be submitted in English.
All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
- Disclosure of Conflicts of Interest: Abstract submitters will be required to disclose any conflict of interests in the submission form.
Instructions for preparation of presentations will be made available on the conference website in due course.
?
Guidelines for Submission
?Before you begin, please prepare the following information:
- ?Presenting author’s contact details:
– Full first and family name(s)
– Email address
– Affiliation details: department, institution / hospital, city state (if relevant), Country
– Phone number
- Author and co-authors’?details
- Preferred Presentation type:?Oral Presentation / Short Oral Presentation / e-Poster
- Abstract title?– must be in?UPPER CASE?and?limited to 25 words.?Please submit symbols as words.
- Abstract text?–?limited to 250 words?including acknowledgments. (Please Note: word count is affected when graphs/tables are included).
- Abstract topic– select the abstract topic per the?list of topics.
- Images– The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format. Note: images don’t affect the word count.
- Abstracts should?clearly state:
Background and aims
Methods
Results
Conclusions?
- Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
- Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
- Submissions may not contain patient names, hospital ID numbers or other identifying information.
- The submission form allows?you to?store your abstract as a?DRAFT?until the deadline.?After the deadline if not submitted, drafts will be deleted.
- Click on the?SUBMIT?button at the end of the process in order to save your abstract. You may log in to the system later to make changes to your abstract, up to the submission deadline.?After the deadline, abstracts cannot be modified or corrected.
- You will receive an abstract ID number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
- Please?contact us?if you have not received confirmation that your abstract has been submitted.
- Please do not submit multiple copies of the same abstract.
?
Abstract Submitters’ Declaration
During abstract submission you will be asked to confirm that you agree to the following:
- I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract?cannot be modified or corrected after final submission?and I am aware that it will be published exactly as submitted.
- Submission of the abstract constitutes?the consent of all authors?to publication (e.g. Conference website, programs, other promotions, etc.)
- The Abstract Submitter warrants and represents that no part of the information and content provided by him/her (Hereafter: the “Content“) to ATTD 2026 and Kenes International (Hereafter: the “Organizers“), nor the publication of any such Content by the Organizers, on the internet or otherwise infringes any third party rights, including but not limited to? intellectual property rights.
- The Abstract Submitter grants each of the Organizers the license and right to use, reproduce, publish, translate, distribute, and display the Content or any part thereof, in any manner and on any platform or media whatsoever, in each Organizer’s absolute discretion, on a royalty-free, perpetual, irrevocable nonexclusive basis.
- I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on abstract correspondence.
- I understand that the presenting author must be a registered participant.
- The Organizers reserve the right to remove from publication and/or presentation an abstract which does not comply with the above.
- I understand that I must select a specific Theme, Topic and/or Sub-Topic for my abstract allocation.? Although the Committee will work hard to honor this selection, this cannot be guaranteed.? The Committee reserves the right to change the Theme, Topic or Sub-Topic under which the abstract was originally submitted.
- I confirm to have received the consent of all authors for the processing of their contact details by Kenes and the Organizers.
Dear Colleagues
It is our pleasure to welcome you to the?19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2026) taking place at the fascinating city of Barcelona, on March 11-14, 2026.
Join us at ATTD 2026, the premier international platform where a diverse community – clinicians, diabetes care providers, researchers, industry, startups, investors, reimbursement authorities, and regulators – collaborates to drive rapid progress in diabetes care.
The conference program features presentations and discussions led by distinguished professionals, covering a wide spectrum of innovations from artificial intelligence and glucose technology to novel therapies and prevention strategies.
We look forward to your contributions and active participation, which will be instrumental in making ATTD 2026 a high-impact and unforgettable occasion.
See you in Barcelona!
Yours sincerely,
Professor Moshe Phillip & Professor Tadej Battelino
Conference Chairpersons
注冊費：
◆ 參會對象：醫(yī)生、醫(yī)院科室主任/副主任、住院醫(yī)師、醫(yī)院管理者、醫(yī)護人員以及從事該領域研究的科學家、研究人員、醫(yī)藥企業(yè)代表等等。
|
